logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Jazz Pharmaceuticals and Zymeworks Product Zanidatamab Advance the Treatment of HER2-expressing mGA

Jazz Pharmaceuticals and Zymeworks Inc Announce Results of Zanidatamab Jazz Pharmaceuticals ( JAZZ ) and  Zymeworks Inc. ( ZYME ) announced first overall survival ( OS ) data from a Phase 2 trial examining zanidatamab. Zanidatamab.is a HER2-targeted bispecific antibody used...

Read More

January 20, 2023

0

Amgen: FDA Approves LUMAKRAS™, the First and Only Targeted Treatment for Patients with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC

Amgen Announced FDA Approval of LUMAKRAS ™   Amgen ( AMGN ) announced the news about the FDA approval of LUMAKRAS™ (sotorasib) on May 28, 2021. The firm indicated that the FDA granted approval is for adults with KRAS G12C-mutated locally...

Read More

May 31, 2021

0

TG Therapeutics Launched FDA Approved Product  BRIUMVI™ for Patients with Relapsing Forms of MS

TG Therapeutics  TG Therapeutics ( TGTX ) is a commercial stage, biopharmaceutical company developing and commercializing novel treatments for B-cell diseases. The firm’s research pipeline has several investigational medicines. TG Therapeutics has been granted U.S. FDA approval of its product BRIUMVI™...

Read More

January 27, 2023

0

Why Merck KGaA, Darmstadt, Germany Paid Sutro Biopharma. See Also: BMY Approval of Zeposia for UC

Sutro Biopharma Receives Milestone Payment from Merck KGaA, Darmstadt, Germany Sutro Biopharma ( STRO ) announced that it has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt,Germany . The payment...

Read More

June 1, 2021

0

Halozyme Therapeutics' Positive Results for Patients with Chronic Inflammatory Demyelinating Polyneuropathy

The way drugs are being delivered into patients’ bodies have become more than ever considered important with regard to the safety and efficacy of the treatments. We consider Halozyme Biopharmaceutical is a leader in bringing disruptive solutions to significantly improve patient...

Read More

July 21, 2023

0

CytomX: Why Does Good News from This Firm Cause Its Stock to Move South Instead of North?

CytomX Therapeutics  We posted several articles that brought good news from CytomX Therapeutics ( CTMX ) , yet the stock continues to go down instead of up.  A few days ago, CytomX announced the achievement of a clinical candidate milestone...

Read More

February 2, 2023

0

TG Therapeutics Will Have An Important Conference Call at 8:30 AM Tomorrow, August 1st

TG Therapeutics Conference Call TG Therapeutics ( TGTX ) announced that, tomorrow, Tuesday, August 1, 2023, a conference call will be held at 8.30 AM ET, to discuss the results of the second quarter 2023 and provide a business outlook...

Read More

July 31, 2023

0

Xenon Pharmaceuticals Reports 2Q 2023 Financial Results and Provides Corporate Update

Xenon Pharmaceuticals Q2 Financial Results On  August 09, 2023 , Xenon Pharmaceuticals ( XENE ) reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. Xenon report started with Mr. Ian Mortimer, the firm’s President and Chief...

Read More

August 15, 2023

0

Evaluating Regenxbio Clinical Performance of RGX-314 Using the Navxpress™ Manufacturing Platform Process

Prohost's Beliefs About the Status of the Market That the market is still volatile and Bear. Investors in the biotech sector who intend to bet on clinical stage firms must restrict their choices to companies that already have proof of...

Read More

February 13, 2023

0

The Biotechnology Revolution: News from Nuvectis Pharma and Revolution Medicines Publication

Nuvectis Pharma Nuvectis Pharma ( NVCT ) is a biopharmaceutical company focused on developing innovative precision targeted drugs capable of treating cancers that have yet to find treatments. The Company’s pipeline comprises two drug candidates, NXP800 and NXP900. NXP800  is...

Read More

August 20, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 45
  • 46
  • 47
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy